View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 3, 2017updated 24 Oct 2017 3:38pm

Transgene and Randox to develop oncolytic treatment for solid tumours

Transgene has a partnered with in-vitro diagnostics company Randox to combine their technologies and develop multifunctional oncolytic immunotherapies.

By Rosanna Jeffery

Transgene has a partnered with in-vitro diagnostics company Randox to combine their technologies and develop multifunctional oncolytic immunotherapies.

New oncolytic viruses (OVs) resulting from the current partnership will use Transgene’s latest viral platform Invir.IO, with one or more of Randox’s single-domain antibodies (SdAbs) will be vectorised.

Advanced immunotherapies will help combine the oncolytic effect of the viruses with properties of the vectorised SdAbs that will be locally expressed in the tumour microenvironment (TME) with the focus on treating patients with immunosuppressed solid tumours.

Randox Laboratories founder and managing director Dr Peter FitzGerald said: “We are looking forward to working with Transgene to generate OVs that will be able to express multiple functions directly into a tumour, enhancing their efficacy.

“This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise and add to our strategic collaborations across the world.”

“This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise and add to our strategic collaborations across the world.”

Under the deal, Transgene will create new anticancer oncolytic virus (OV) drugs by using its Vaccinia virus (TK-, RR-) strain, and its skill in molecular engineering and translational research.

The new viral strain provides increased oncolytic properties and its large genome capacity allows multiple therapeutic payloads (anticancer weapons) to be delivered in a tumour, where the virus replicates.

In addition, Randox will offer expertise in antibody engineering and provide access to its collection of new and future immunotherapeutic SdAbs to be used as vectorised payloads.

The SdAbs will be able to modulate the patient’s immune response and generate a synergistic effect with Transgene’s oncolytic viral platform.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology